Value is defined as desirable health outcomes achieved per monetary unit spent. Comparative effectiveness research and costeffectiveness research are methods that have been developed to quantify effectiveness and value to inform management decisions. In this article we review the comparative and cost-effectiveness literature in the field of ovarian cancer treatment. Studies have shown that improved ovarian cancer survival is associated with complete primary surgical cytoreduction, with treatment at high volume facilities by subspecialist providers (gynecologic oncologists) and with National Comprehensive Cancer Network (NCCN) guidelineadherent care in both surgical staging and chemotherapy regimens. Intraperitoneal/intravenous chemotherapy (compared with intravenous alone) has been associated with improved survival and cost-effectiveness. Bevacizumab for primary and maintenance therapy has been found to not be cost-effective (even in selective subsets) despite a small progression-free survival (PFS) advantage. For platinum-sensitive recurrent ovarian cancer, secondary cytoreduction and platinum-based combinations are associated with improved overall survival (OS); several platinum-based combinations have also been found cost-effective. For platinum-resistant recurrence, single agent therapy and supportive care are cost-effective compared with combination therapies. Although little prospective clinical research has been done around end-of-life care, one study reported that for platinum-resistant ovarian cancer, palliative intervention would potentially reduce costs and increase quality adjusted life years compared with usual care (based on improvement in quality of life [QOL]). Overall, cost comparisons of individual chemotherapy regimens are highly dependent on market prices of novel therapeutic agents.
T he high cost of health care in the United States without demonstration of superior health outcomes when compared with other developed countries has brought increasing pressure on health systems and providers to demonstrate "value." Value can be defıned broadly as the desirable health outcomes achieved per monetary unit spent. 1 Ideally, a valuebased reimbursement system would replace the current system of payment for services provided.
DEFINING VALUE IN HEALTH CARE
Harvard economist Michael E. Porter argues that the defıni-tion and demonstration of value is integral to reining in costs, and to overall health care reform. He states that, "the absence of comprehensive and rigorous outcome and cost measurement is arguably the biggest weakness standing in the way of health care improvement." 1 In an effort to begin to defıne high quality outcomes, Porter has developed an idealized outcomes measures hierarchy, in which specifıc health outcomes are multitiered and defıned for each disease. In oncology, the highest priority is assigned to survival, followed by functional status achieved, recovery times following treatment, effect of the treatment process on function and QOL, and sustainability of the cancer-free state. Costs are defıned as they apply to a full optimal cycle of care for a given medical condition, usually representing periods of a year or more. Responsibility for outcomes and reimbursements are shared by all participating providers for a given heath condition.
VALUE AND COMPARATIVE EFFECTIVENESS RESEARCH
Given that the ideal infrastructure for measuring value does not yet exist, how can we conduct outcomes-based research with the goal of improving health care quality? The concept of comparative effectiveness research (CER) grew from concerns about the health care budget and the need to restrain spending while retaining health care quality and outcomes. The Patient Protection and Affordable Care Act (ACA) of 2010 described comparative effectiveness research as a central feature of federal efforts to improve health care.
The Institute of Medicine committee defınes CER as "the generation and synthesis of evidence that compares the benefıts and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care. The purpose of CER is to assist consumers, clinicians, purchasers, and policy makers to make informed decisions that will improve health care at both the individual and population levels." 2 As described by Chandra et al, "Put simply, comparative effectiveness research compares the effıcacy of two or more diagnostic tests, treatments, or health care delivery methods without any explicit consideration of costs." 3 CER encompasses numerous research methodologies, and has its origins in clinical research, outcomes research, decision analysis, and health services research. As defıned by Garber and Sox, CER has four guiding principles: the use of real world settings, the use of representative (as opposed to ideal) populations, the consideration of personalization of health care, and the measurement of all outcomes that are important to patients. 2 
IS COST A CONSIDERATION IN COMPARATIVE EFFECTIVENESS RESEARCH?
As strictly defıned and enforced by the ACA of 2010, CER does not include consideration of cost. As a result of concerns raised about resource rationing and the devaluation of life in health states with a high burden of disability, the ACA stated that "The Patient-Centered Outcomes Research Institute (PCORI) … shall not develop or employ a dollars-per-quality adjusted life year (or similar measure that discounts the value of a life because of an individual's disability) as a threshold to establish what type of health care is cost-effective or recommended." 2 This means that PCORI, the institute that was created in response to concerns about the high cost of health care in the US, is prohibited from sponsoring studies that include considerations of cost-effectiveness. Despite this, several experts have argued that the funding of CER still provides quality evidence for employment in standard costeffectiveness analyses and will therefore ultimately inform the question of value in health care. 3 
COST-EFFECTIVENESS STUDIES: USEFUL TERMINOLOGY
This section contains a brief introduction to costeffectiveness terminology. Because they are usually constructed to determine the advisability of funding costly interventions compared with the standard of care, costeffectiveness studies in health care are traditionally conducted from the perspective of society or a third party payer. In a cost-effectiveness study, the perspective of each study should always be stated; alternative perspectives that may be used include that of the patient or another party such as a hospital. Studies evaluating the cost and cost-effectiveness of health care interventions may fall into several classifıcations. Cost-effectiveness analysis (CEA) is a generic term that encompasses a comparison of the costs and effectiveness of at least two alternative strategies. In oncology, effectiveness is often quantifıed as survival time. A cost-utility analysis (CUA) is a CEA that also specifıcally accounts for healthrelated quality of life through the incorporation of utilities. A utility is a numeric representation of the quality of life spent in a specifıc health state, and is generally a number between 0 (dead) and 1 (perfect health). A cost minimization analysis compares the relative costs of two strategies, usually under the assumption of equivalent effectiveness. 4 Cost-effectiveness studies use the incremental costeffectiveness ratio (ICER) as their primary outcome metric. The ICER is the ratio of incremental costs to incremental effectiveness between two strategies. It is most appropriately expressed in monetary units per QALY. 5 QALYs represent the product of time spent in a health state and the utility associated with that state. Cost-effectiveness studies that do not account for quality of life may also use the outcome metric monetary units per year of life saved. An ICER may alternatively be expressed as any ratio of the burdens of an intervention divided by the benefıts. For example, the number of additional cases of lymphedema per prevented death from cancer at fıve years might be used to quantify the ICER of lymphadenectomy compared with no lymphadenectomy. 6 However, the advantage of using a more traditional ICER is that this allows a comparison to standard societal willingness to pay ratios. In the US, $50,000 to $100,000/QALY is usually considered to be an acceptable willingness to pay threshold, with some arguing the appropriateness of higher thresholds 3, 4, 7 
COMPARATIVE EFFECTIVENESS STUDIES IN OVARIAN CANCER
Randomized controlled trials (RCTs) are the gold standard regarding our knowledge of the effects of specifıc treatments on women with gynecologic cancer. However, RCTs are not always practical and usually address effects on the "ideal" rather than the "real" patient. For the purposes of this overview of the existing evidence on quality and value in gynecologic cancer care, we will focus on comparative effectiveness studies in ovarian cancer that use health services methodol-
KEY POINTS
⅐ Value in health care is broadly defined as desirable health outcomes achieved per monetary unit spent. ⅐ The Affordable Care Act determined that Comparative Effectiveness Research should compare the benefits and harms of medical interventions without consideration of costs. ⅐ Cost-effectiveness research measures costs per outcome achieved, usually in quality-adjusted life years (QALYs). ⅐ The comparative effectiveness literature supports that higher quality care from ovarian cancer is achieved when surgery is performed at high volume centers and a gynecologic oncologist is part of the care team. ⅐ The cost-effectiveness of chemotherapy regimens is highly dependent on the market cost of novel agents.
ogy and large databases, cost and cost-effectiveness studies, and systematic reviews/meta-analyses of more than one study (Table 1) . Single institution experiences are excluded, as are stand-alone RCTs.
Primary Surgery and Process of Care
The setting and manner of primary surgery for ovarian cancer has been the subject of widespread study. In a metaanalysis of 18 studies published from 1996 to 2011 and over 13,000 patients to evaluate factors predictive of survival in advanced ovarian cancer, Chang et al found that complete surgical cytoreduction was associated with improved survival. 8 The process of ovarian cancer care has also been examined frequently in CER studies. Bristow et al employed a health services approach to investigate associations between patterns of care and survival among women with ovarian cancer. In a study of over 11,000 women with advanced stage ovarian cancer in the California Cancer Registry (CCR), the authors found that the combination of treatment at a high volume hospital (20 cases/year) and treatment by a high volume provider (10 cases/year) was associated with improved cancer-specifıc survival. 9 The authors also identifıed racial disparities that were associated with both cancer-specifıc survival and the likelihood of undergoing important staging procedures. 10 In a similar study of over 13,000 patients from the CCR, NCCN guideline-adherent care-defıned by appropriate surgical staging procedures and recommended chemotherapy-was found to be associated with improved cancer-specifıc survival. 11 In a separate study of over 47,000 patients in the National Cancer Data Base, NCCN-adherent care was again associated with improved OS. 12 The importance of care by a gynecologic oncologist has also been evaluated in multiple studies. Chan et al evaluated over 1,400 women with ovarian cancer in the CCR and found that care by a gynecologic oncologist was associated with improved cancer-specifıc survival. 13 A Cochrane meta-analysis of three studies with over 9,000 patients found that care in a hospital with gynecologic oncologists on site was associated with prolonged survival in women with ovarian cancer (hazard ratio [HR], 0.90; 95% CI, 0.82 to 0.99). 14 Bristow et al performed a CUA comparing a scenario of centralized care in which women with ovarian cancer received referral to an expert center with a high rate of optimal surgical cytoreduction and utilization of combined intraperitoneal and intravenous adjuvant chemotherapy, versus referral to a less experienced center with a lower rate of optimal cytoreduction and only intravenous adjuvant chemotherapy. The centralization scenario was found to be cost-effective. 15 Chan et al evaluated over 6,000 women with clinical early stage ovarian cancer in the Surveillance, Epidemiology, and End Results (SEER) database and found that lymphadenectomy was associated with improved disease-specifıc survival. 16 
Primary Chemotherapy
Two large CER studies have examined the importance of platinum-based primary chemotherapy for ovarian cancer.
Du et al performed a comparative effectiveness analysis of chemotherapy regimens in 12,181 women with stage I to IV ovarian cancer in the SEER and Medicare linked databases. Receipt of both a platinum and a taxane was associated with improved all cause mortality (HR, 0.66; 95% CI, 0.55 to 0.79). The study's major limitations were possible sampling bias in the comorbidities, socioeconomic level, and age distribution of the Medicare subset. 17 A Cochrane pooled analysis of over 8,000 patients found a nonsignifıcant trend toward improved survival in ovarian cancer treated with a platinum-based regimen (HR, 0.93; 95% CI, 0.83 to 1.05). 18 Intraperitoneal chemotherapy has been considered a standard regimen, particularly for optimally debulked advanced stage ovarian cancer. A Cochrane review of nine RCTs including 2,119 women reported that women treated with intraperitoneal chemotherapy had improved OS (HR, 0.81; 95% CI, 0.72 to 0.90) compared with those treated with intravenous chemotherapy. 19 Similarly, Chang et al performed a meta-analysis of 18 studies published from 1996 to 2011 and over 13,000 patients to evaluate factors predictive of survival in advanced ovarian cancer. The authors found that receipt of intraperitoneal chemotherapy was associated with improved survival. 8 Two studies have examined the cost-effectiveness of intraperitoneal/intravenous chemotherapy for women with optimally debulked stage III ovarian cancer. Bristow et al reported an ICER of $37,454 per QALY comparing intraperitoneal/intravenous to intravenous chemotherapy and noted that most of the cost of intraperitoneal/intravenous treatment was accounted for by the inpatient requirement of the intraperitoneal regimen in clinical trials performed at that time. 20 Havrilesky et al similarly noted that high costs were associated with inpatient intraperitoneal/intravenous chemotherapy and reported that intraperitoneal/intravenous had an ICER of $32,053/QALY compared with intravenous over a lifetime horizon. Both studies concluded that outpatient intraperitoneal regimens had the potential to be even more cost-effective under the assumption that effectiveness was preserved. 21 Dose-dense paclitaxel has been shown to be associated with OS when compared with every 3-week paclitaxel in a Japanese Gynecologic Oncology Group (GOG) trial of primary chemotherapy. 22 Dalton et al examined the potential costeffectiveness of this regimen and found it to be highly costeffective, with an ICER of $5,809 per progression-free year of life saved, compared with every 3-week paclitaxel. As the results of GOG 262 have not yet been published, it remains unclear whether dose-dense weekly paclitaxel might be considered cost-effective under the conditions of that study. 23 
Novel Primary Therapies
Two RCTs published in parallel in 2011 (GOG 218 and ICON7) reported that a small PFS advantage was associated with the addition of bevacizumab in combination with platinum-based intravenous chemotherapy and as maintenance following completion of chemotherapy. 24, 25 Cohn et al performed a CEA modeling the structure and results of GOG 218 before the publication of the QOL results. The authors found that the addition of bevacizumab was not costeffective, with an ICER exceeding $400,000/progression-free year of life. It was estimated that a reduction in the cost of bevacizumab to 25% of its current reimbursement would be necessary to meet minimum willingness to pay thresholds standards. 26 A subsequent cost-utility study incorporating QOL reinforced the very high ICER of combination and maintenance bevacizumab for all patients with advanced ovarian cancer. 27 A second CUA explored the possibility of selecting a subset of high risk patients for treatment with bevacizumab, based on a subset analysis of the ICON7 trial that showed that women with stage IV and suboptimally debulked stage III disease had an overall survival advantage when treated with bevacizumab. This model found that a strategy of treating only the high-risk subset with bevacizumab was also not cost-effective, with an ICER of $168,000/ QALY. This model also suggested that developing a predictive test to determine treatment with bevacizumab may have the potential to improve the cost-effectiveness of the selective use of bevacizumab, with an ICER of $129,000/ QALY. 28 
Maintenance Chemotherapy
Maintenance chemotherapy, or administration of further chemotherapy after achievement of a complete primary response, has been the subject of some controversy because of the additional toxicity of prolonging the treatment period. Despite an RCT (GOG 178) showing a PFS advantage with 12 versus 3 months of maintenance paclitaxel, 29 a Cochrane review evaluating 1,644 women enrolled in trials of maintenance chemotherapy for ovarian cancer found no signifıcant PFS or overall survival (OS) advantage at 3, 5, or 10 years with the addition of maintenance platinum, doxorubicin, or paclitaxel. The authors concluded that further studies were need regarding the effects of paclitaxel as maintenance. 30 A CUA using data from GOG 218 and GOG 178 compared the cost-effectiveness of carboplatin, paclitaxel, and bevacizumab (combination and maintenance) versus carboplatin/ paclitaxel followed by maintenance paclitaxel. The authors reported that maintenance paclitaxel is very cost-effective at $13,402/QALY compared with no maintenance therapy, whereas the maintenance bevacizumab arm was not costeffective at $326,530/QALY. 31 
Surgery for Recurrent Ovarian Cancer
Ovarian cancer recurrence may be managed by observation until symptoms develop, then treated with medical treatment using chemotherapy or biologic agents, or by surgery. A Cochrane systematic review evaluated the role of secondary surgical debulking of recurrent ovarian cancer. In nine nonrandomized trials of over 1,100 women, complete cytoreduction was associated with improved OS. However the potential for bias and the lack of randomized data were noted as important limitations to interpretation. 32 Chuang et al have also performed a comparative effectiveness analysis of secondary cytoreduction using an administrative database of 1,124 patients with recurrent ovarian cancer. The authors reported that secondary cytoreduction was associated with improved OS (HR, 0.76; 95% CI, 0.66 to 0.87). 33 
Therapies for Recurrent Ovarian Cancer
In RCTs, platinum-based combinations have been shown to improve survival outcomes for women with platinumsensitive recurrent ovarian cancer. [34] [35] [36] [37] Several costeffectiveness studies have evaluated chemotherapy regimens for recurrent ovarian cancer. Case et al performed a CEA in which second-line combination chemotherapy was found to be cost-effective compared with monotherapy (ICER $46,068/year of life saved). 38 Havrilesky et al demonstrated the cost-effectiveness of carboplatin/paclitaxel compared with carboplatin in this setting, but found that carboplatin/ gemcitabine exceeded the common willingness to pay thresholds as a result of the higher cost of gemcitabine at that time. 39 Lee et al subsequently reported that liposomal doxorubicin/carboplatin was cost-effective compared with paclitaxel/carboplatin in this setting, with an ICER of $21,658/ QALY. 40 A set of novel agents currently being tested in the concurrent and maintenance setting for ovarian cancer are the poly-(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors. 41 Secord et al performed a CEA comparing observation with olaparib for maintenance treatment of platinumsensitive recurrence following a response to platinum-based chemotherapy. Olaparib costs were estimated based on the costs of biologic agents that have recently been marketed for advanced malignancies. Olaparib was not found to be costeffective, with an ICER $200,000/progression-free year compared with observation. The authors also examined a strategy of BRCA 1/2 testing to determine olaparib use. Nor was this strategy cost-effective, with an ICER of $193,442 compared with no olaparib. However, BRCA 1/2 testing was costeffective when compared with global treatment with olaparib (instead of comparing to observation). 42 For women with platinum-resistant recurrence, Rocconi et al demonstrated that the most cost-effective strategy is either single agent therapy or best supportive care, rather than combination therapies. 43 
End of Life
There has been an intense focus on end-of-life care in oncology, with one prominent RCT demonstrating both improved QOL and longer survival in patients with small cell lung cancer who were randomly assigned to early palliative care intervention at the time of their initial cancer diagnosis. 44 ASCO guidelines suggest the initiation of palliative care services at the time of initial diagnosis of metastatic cancer. 45 Single institution studies have shed light on the currently inadequate state of palliative services in gynecologic cancers, but no large health services CER studies have been reported. [46] [47] [48] Lowery et al performed a cost-effectiveness analysis comparing palliative care intervention with usual care for women with platinum-resistant ovarian cancer. The relative effects of palliative care intervention on end-of-life resource utilization and QOL were modeled based on the landmark RCT by Temel et al in lung cancer. 44 No survival effect was assumed. Rates of each outcome were based on the ovarian cancer literature. The authors found that palliative intervention in the platinum-resistant population was a dominant strategy, potentially reducing costs and increasing QALYs (based on improvement in QOL). 49 
CONCLUSION
Value is best defıned as desirable health outcomes achieved per monetary unit spent. CER and cost-effectiveness research are methods that have been developed to quantify value, thereby guiding management decisions. CER and CEA studies in ovarian cancer support the value of comprehensive surgical resection of primary disease, care by a gynecologic oncologist, and the use of intraperitonal chemotherapy for optimally debulked advanced disease. Cost comparisons of individual chemotherapy regimens are highly dependent on the market cost of drugs, with recent high profıle biologic agents not meeting standard societal willingness to pay thresholds. Palliative care at the end of life appears to provide high value at lower cost.
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